BPC-157 is the most searched peptide on the internet and the one with the widest gap between what is claimed and what has been tested in people. This page lists the human evidence in full, because it is short, and then the regulatory record, because that is where the real news has been.
What it is
BPC stands for Body Protection Compound. BPC-157 is a 15-amino-acid sequence derived from a protein found in human gastric juice, synthesised and studied since the early 1990s, mostly by one research group in Zagreb. The animal literature is large: tendon, ligament, muscle, bone, gut, liver and nervous-system injury models in rats, with reported effects on angiogenesis, nitric-oxide pathways and growth-hormone receptor expression. A 2025 literature and patent review (PubMed 40005999) catalogues it.
Rats are where the story stays. A 2025 systematic review in HSS Journal (PubMed 40756949) searched PubMed, Cochrane and Embase from inception to June 2024 and found 544 articles. After screening, 36 studies met inclusion: 35 preclinical and 1 clinical.
The human evidence, all of it
We searched PubMed for BPC-157 studies in humans on September 4, 2026. Three reports, all from the same private clinic in Florida, all uncontrolled:
| Year | Design | What it can and cannot show | PubMed |
|---|---|---|---|
| 2021 | Retrospective one-year chart review of patients given intra-articular injections for knee pain | Patients reported less pain. No control group, no blinding, no standard outcome, retrospective selection. | 34324435 |
| 2024 | Open-label pilot, 12 women with interstitial cystitis | 10 of 12 reported complete symptom resolution on a self-rated scale. No control group; the condition fluctuates and responds strongly to expectation. | 39325560 |
| 2025 | Two adults given intravenous infusions on consecutive days, blood markers before and after | No change in the measured heart, liver, kidney, thyroid or glucose markers over three days in two people. It is a two-person safety check, not a safety study. | 40131143 |
That is the complete indexed human record. No randomised trial, no placebo, no independent replication, no pharmacokinetics in humans.
Regulatory status
On September 29, 2023 FDA placed BPC-157 in Category 2 of the substances nominated for the 503A bulks list. Category 2 means FDA identified significant safety risks. Its stated concerns, still published on the Category 2 page as of April 22, 2026: risk of immunogenicity for certain routes of administration, complexities with peptide-related impurities and API characterisation, and no or only limited safety-related information for the proposed routes, so that FDA "lacks sufficient information to know whether the drug would cause harm when administered to humans."
FDA's page now lists BPC-157 under "nominated but withdrawn." That is not an upgrade. It means the nomination was withdrawn or moved into the committee process; the concerns stay on the page, and BPC-157 is not in Category 1 and not on the 503A bulks list.
On July 23, 2026 the Pharmacy Compounding Advisory Committee discussed BPC-157 (free base and acetate) with ulcerative colitis as the use FDA evaluated. FDA's meeting page carries the agenda and briefing materials. As of our check it did not publish a vote tally, and we do not repeat the numbers reported in trade press. Whatever the committee recommended, a recommendation is step two of three; a substance is not on the list until a final rule says so. Our compounding site explains the 503A bulks list process and the research-use-only labelling under which BPC-157 is actually sold.
Safety signals
There is no human safety data set to summarise. FDA's concern is exactly that. The 2025 systematic review describes the preclinical safety profile as favourable and notes that this has not been established in humans. The angiogenesis and growth-factor mechanisms that make BPC-157 interesting in wound models are the same mechanisms a regulator would want studied around tumour growth before human use; no such study exists.
Grade: D + X
D because there is no controlled human study for any use. X because FDA has published a specific safety concern for the substance in compounding. The grading scale explains both rules. Check the current status in the evidence grade lookup; if FDA completes rulemaking, the status field changes before the grade does.
Questions people ask
Has BPC-157 been tested in a randomised human trial?
Not in any publication indexed in PubMed as of September 4, 2026. A 2025 systematic review (PubMed 40756949) found 36 eligible studies, 35 of them preclinical and one clinical. The human reports we located are uncontrolled: a retrospective chart review, a 12-patient open-label pilot and a two-person infusion safety report.
Is BPC-157 FDA approved or legal to compound?
It is not FDA approved. FDA placed it in Category 2 of the 503A bulks list on September 29, 2023, citing immunogenicity risk and a lack of safety data, and now shows it as nominated but withdrawn, with the concerns still published. It is not on the 503A bulks list. The Pharmacy Compounding Advisory Committee discussed it on July 23, 2026; only a final rule would change what a pharmacy may use.
Why does this page give no dose?
Because there is no human dose. No regulator has reviewed one, no controlled trial has established one, and publishing one alongside storage or reconstitution instructions is what FDA treats as marketing an unapproved drug for human use. This site does not do that for any research-only compound.
Sources
- FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (content current as of April 22, 2026) Accessed September 4, 2026.
- FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026) Accessed September 4, 2026.
- Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PubMed 40756949 Accessed September 4, 2026.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med 2021. PubMed 34324435 Accessed September 4, 2026.
- Lee E et al. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med 2024. PubMed 39325560 Accessed September 4, 2026.
- Lee E et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PubMed 40131143 Accessed September 4, 2026.
- Jozwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals 2025. PubMed 40005999 Accessed September 4, 2026.
Canonical URL: https://formblendspeptides.com/peptides/bpc-157. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.